Drug development: raise standards for preclinical cancer research | Homeopathy Discussion Forums

Ask Questions about Health, Homeopathy, Medicine – Get Answers from Experts and Peers!


Please consider registering

sp_LogInOut Log In sp_Registration Register

Register | Lost password?
Advanced Search

— Forum Scope —

— Match —

— Forum Options —

Minimum search word length is 3 characters - maximum search word length is 84 characters

sp_Feed sp_TopicIcon
Drug development: raise standards for preclinical cancer research
No permission to create posts
Topic Rating: 0 Topic Rating: 0 (0 votes) 
April 15, 2012
9:19 pm
Forum Posts: 164
Member Since:
December 19, 2011
sp_UserOfflineSmall Offline
by: Pharm-line

Efforts over the past decade to characterise the genetic alterations in human cancers have led to a better understanding of molecular drivers of this complex set of diseases.  Although researchers in the cancer field hoped that this would lead to more effective drugs, the ability to translate cancer research to clinical success has been remarkably low, and clinical trials in oncology have the highest failure rate compared with other therapeutic areas.

A significant contributor to failure in oncology trials is the quality of published preclinical data.  Drug development relies heavily on the literature, especially with regard to new targets and biology.  Moreover, clinical endpoints in cancer are defined mainly in terms of patient survival, rather than by the intermediate endpoints seen in other disciplines (for example, cholesterol levels for statins).  Thus, it takes many years before the clinical applicability of initial preclinical observations is known.  The results of preclinical studies must therefore be very robust to withstand the rigours and challenges of clinical trials, stemming from the heterogeneity of both tumours and patients.

Scientists (including one of the authors) in the haematology and oncology department at the biotechnology firm Amgen (Thousand Oaks, California, USA) tried to confirm published findings related to their work.  53 papers were deemed ‘landmark’ studies but scientific findings were confirmed in only 6 (11%) cases.

Thess findings are consistent with those of others in industry.  A team in Germany recently reported that only about 25% of published preclinical studies could be validated to the point at which projects could continue.  Notably, published cancer research represented 70% of the studies analysed in that report, some of which might overlap with the 53 papers examined at Amgen.  Some non-reproducible preclinical papers had spawned an entire field, with hundreds of secondary publications that expanded on elements of the original observation, but did not actually seek to confirm or falsify its fundamental basis.  More troubling, some of the research has triggered a series of clinical studies – suggesting that many patients had been subjected to a trial of a regimen or agent that probably wouldn’t work.

The authors suggest  ways in which preclinical research could be made more robust, but conclude that the responsibility for design, analysis and presentation of data rests with investigators, the laboratory and the host institution.  All are accountable for poor experimental design, a lack of robust supportive data or selective data presentation.  The scientific process demands the highest standards of quality, ethics and rigour.





Forum Timezone: UTC 5.5

Most Users Ever Online: 231

Currently Online:
2 Guest(s)

Currently Browsing this Page:
1 Guest(s)

Top Posters:

David Kempson: 775

drofart: 769

Manish Bhatia: 667

in need of help2: 373

Firuzi Mehta: 335

In need of help: 308

inquisitivegirl: 196

Elaine Lewis: 180

patti: 177

Surabhi Sharma: 164

Member Stats:

Guest Posters: 27

Members: 4387

Moderators: 6

Admins: 2

Forum Stats:

Groups: 4

Forums: 17

Topics: 1557

Posts: 9080

Newest Members:

jamesannie, Angel White, ritatono, swati28, Dr. Devina, Paola Meli, huaioejd25, Kelli Revoir, Neerja Kapoor, veggielover

Moderators: Alan V. Schmukler: 992, Rochelle: 200, David A. Johnson: 38, John: 18, Shirley Reischman: 193, Pankaj Titar: 7

Administrators: Manish Bhatia: 0, Hpathy.com: 0